Semaglutide 2.4  mg/wk for weight loss in patients with severe obesity and with or without a history of bariatric surgery

CONCLUSIONS: This study is the first, to the authors' knowledge, to compare the effectiveness of semaglutide treatment in patients with versus those without a history of BS, providing valuable evidence of its efficacy. By focusing on individuals with severe obesity (BMI > 40 kg/m2 and associated comorbidities), it fills a gap in the current literature and highlights the potential of semaglutide 2.4 mg as a treatment option for this specific population.PMID:37927153 | DOI:10.1002/oby.23922

Source: Obesity - November 6, 2023 Category: Eating Disorders & Weight Management Authors: Jean-Baptiste Bonnet Sarah Tournayre Jean Anitcheou Marion Faivre Catherine Boegner Abdulkader Jalek Dominique Jullien Vincent Attalin Justine Myzia Lucile Marty Youadigue Kemba David Nocca Ariane Sultan Antoine Avignon Source Type: research